Compare ZDAI & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZDAI | SNGX |
|---|---|---|
| Founded | 2022 | 1987 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | General Bldg Contractors - Nonresidential Bldgs | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.8M | 13.8M |
| IPO Year | 2024 | 1987 |
| Metric | ZDAI | SNGX |
|---|---|---|
| Price | $0.35 | $1.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 100.0K | ★ 293.5K |
| Earning Date | 12-23-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $19,275,673.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 43.16 | N/A |
| 52 Week Low | $0.33 | $1.09 |
| 52 Week High | $1.85 | $6.23 |
| Indicator | ZDAI | SNGX |
|---|---|---|
| Relative Strength Index (RSI) | 34.30 | 56.47 |
| Support Level | $0.33 | $1.49 |
| Resistance Level | $0.39 | $1.60 |
| Average True Range (ATR) | 0.03 | 0.12 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 16.83 | 85.37 |
DirectBooking Technology Co Ltd, formerly Primega Group Holdings Ltd is engaged in transportation services. It operates in the Hong Kong construction industry, mainly handling the transportation of materials excavated from construction sites. Its services principally comprise (i) soil and rock transportation services; (ii) diesel oil trading; and (iii) construction works, which mainly include ELS works and bored piling. The company provide services as a subcontractor to other construction contractors in Hong Kong. Maximum revenue is generated from soil and rock transportation services.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).